» Articles » PMID: 23741446

Cholecalciferol (vitamin D₃) Improves Myelination and Recovery After Nerve Injury

Overview
Journal PLoS One
Date 2013 Jun 7
PMID 23741446
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Previously, we demonstrated i) that ergocalciferol (vitamin D2) increases axon diameter and potentiates nerve regeneration in a rat model of transected peripheral nerve and ii) that cholecalciferol (vitamin D3) improves breathing and hyper-reflexia in a rat model of paraplegia. However, before bringing this molecule to the clinic, it was of prime importance i) to assess which form - ergocalciferol versus cholecalciferol - and which dose were the most efficient and ii) to identify the molecular pathways activated by this pleiotropic molecule. The rat left peroneal nerve was cut out on a length of 10 mm and autografted in an inverted position. Animals were treated with either cholecalciferol or ergocalciferol, at the dose of 100 or 500 IU/kg/day, or excipient (Vehicle), and compared to unlesioned rats (Control). Functional recovery of hindlimb was measured weekly, during 12 weeks, using the peroneal functional index. Ventilatory, motor and sensitive responses of the regenerated axons were recorded and histological analysis was performed. In parallel, to identify the genes regulated by vitamin D in dorsal root ganglia and/or Schwann cells, we performed an in vitro transcriptome study. We observed that cholecalciferol is more efficient than ergocalciferol and, when delivered at a high dose (500 IU/kg/day), cholecalciferol induces a significant locomotor and electrophysiological recovery. We also demonstrated that cholecalciferol increases i) the number of preserved or newly formed axons in the proximal end, ii) the mean axon diameter in the distal end, and iii) neurite myelination in both distal and proximal ends. Finally, we found a modified expression of several genes involved in axogenesis and myelination, after 24 hours of vitamin supplementation. Our study is the first to demonstrate that vitamin D acts on myelination via the activation of several myelin-associated genes. It paves the way for future randomised controlled clinical trials for peripheral nerve or spinal cord repair.

Citing Articles

Pediatric Bell's Palsy: Prognostic Factors, Management Strategy, and Treatment Outcomes.

Di Sarno L, Caroselli A, Graglia B, Causio F, Gatto A, Pansini V J Clin Med. 2025; 14(1.

PMID: 39797160 PMC: 11722001. DOI: 10.3390/jcm14010079.


Cerebral white matter damage in patients with end-stage kidney disease associates with cognitive impairment.

Hou Y, Tsai C, Chen R, Liu Y, Lu K, Chen Y Clin Kidney J. 2025; 18(1):sfae283.

PMID: 39781476 PMC: 11704783. DOI: 10.1093/ckj/sfae283.


The therapeutic potential of 1, 25-dihydroxy vitamin D3 on cisplatin-affected neurological functions is associated with the regulation of oxidative stress and inflammatory markers as well as levels of MMP2/9.

Niapour A, Abdollahzadeh M, Ghaheri Fard S, Saadati H Metab Brain Dis. 2024; 39(6):1189-1200.

PMID: 39017968 DOI: 10.1007/s11011-024-01382-z.


Exploring the Significance of Vitamin D Levels as a Biomarker in Ear Diseases: A Narrative Review.

Hamayal M, Khurshied S, Zahid M, Khurshid N, Shahid W, Ali M Cureus. 2024; 16(2):e54812.

PMID: 38529449 PMC: 10962011. DOI: 10.7759/cureus.54812.


Unprecedented effect of vitamin D3 on T-cell receptor beta subunit and alpha7 nicotinic acetylcholine receptor expression in a 3-nitropropionic acid induced mouse model of Huntington's disease.

Manjari S, Abraham S, Poornima R, Chaturvedi R, Maity S, Komal P IBRO Neurosci Rep. 2024; 15:116-125.

PMID: 38204575 PMC: 10776327. DOI: 10.1016/j.ibneur.2023.07.001.


References
1.
Birling M, Tait S, Hardy R, Brophy P . A novel rat tetraspan protein in cells of the oligodendrocyte lineage. J Neurochem. 1999; 73(6):2600-8. DOI: 10.1046/j.1471-4159.1999.0732600.x. View

2.
Stumpf W, OBrien L . 1,25 (OH)2 vitamin D3 sites of action in the brain. An autoradiographic study. Histochemistry. 1987; 87(5):393-406. DOI: 10.1007/BF00496810. View

3.
Cannell J, Hollis B, Sorenson M, Taft T, Anderson J . Athletic performance and vitamin D. Med Sci Sports Exerc. 2009; 41(5):1102-10. DOI: 10.1249/MSS.0b013e3181930c2b. View

4.
Rosso S, Bollati F, Bisbal M, Peretti D, Sumi T, Nakamura T . LIMK1 regulates Golgi dynamics, traffic of Golgi-derived vesicles, and process extension in primary cultured neurons. Mol Biol Cell. 2004; 15(7):3433-49. PMC: 452595. DOI: 10.1091/mbc.e03-05-0328. View

5.
Burton J, Kimball S, Vieth R, Bar-Or A, Dosch H, Cheung R . A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010; 74(23):1852-9. PMC: 2882221. DOI: 10.1212/WNL.0b013e3181e1cec2. View